Literature DB >> 22331267

Genomic analysis of high-risk smoldering multiple myeloma.

Lucía López-Corral1, María Victoria Mateos, Luis A Corchete, María Eugenia Sarasquete, Javier de la Rubia, Felipe de Arriba, Juan-José Lahuerta, Ramón García-Sanz, Jesús F San Miguel, Norma C Gutiérrez.   

Abstract

Smoldering myeloma is an asymptomatic plasma cell dyscrasia with a heterogeneous propensity to progress to active myeloma. In order to investigate the biology of smoldering myeloma patients with high risk of progression, we analyzed the genomic characteristics by FISH, SNP-arrays and gene expression profile of a group of patients with high-risk smoldering myeloma included in a multicenter randomized trial. Chromosomal abnormalities detected by FISH and SNP-arrays at diagnosis were not associated to risk of progression to symptomatic myeloma. However, the overexpression of four SNORD genes (SNORD25, SNORD27, SNORD30 and SNORD31) was correlated with shorter time to progression (P<0.03). When plasma cells from high-risk smoldering patients who progressed to symptomatic myeloma were sequentially analyzed, newly acquired lesions together with an increase in the proportion of plasma cells carrying a given abnormality were observed. These findings suggest that gene expression profiling is a valuable technique to identify smoldering myeloma patients with high risk of progression. (Clinical Trials NCT00443235).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22331267      PMCID: PMC3436247          DOI: 10.3324/haematol.2011.060780

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  22 in total

1.  Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma.

Authors:  Laura Rosiñol; Ana Carrió; Joan Bladé; Rosa Queralt; Marta Aymerich; Ma Teresa Cibeira; Jordi Esteve; Maria Rozman; Elías Campo; Emili Montserrat
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

2.  MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.

Authors:  S Vincent Rajkumar
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

3.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

4.  Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis.

Authors:  N C Gutiérrez; M V Castellanos; M L Martín; M V Mateos; J M Hernández; M Fernández; D Carrera; L Rosiñol; J M Ribera; J M Ojanguren; L Palomera; S Gardella; L Escoda; J C Hernández-Boluda; J L Bello; J de la Rubia; J J Lahuerta; J F San Miguel
Journal:  Leukemia       Date:  2006-10-05       Impact factor: 11.528

5.  A monoclonal gammopathy precedes multiple myeloma in most patients.

Authors:  Brendan M Weiss; Jude Abadie; Pramvir Verma; Robin S Howard; W Michael Kuehl
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

6.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Authors:  Ernesto Pérez-Persona; María-Belén Vidriales; Gema Mateo; Ramón García-Sanz; Maria-Victoria Mateos; Alfonso García de Coca; Josefina Galende; Guillermo Martín-Nuñez; José M Alonso; Natalia de Las Heras; José M Hernández; Alejandro Martín; Consuelo López-Berges; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2007-06-18       Impact factor: 22.113

7.  SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer.

Authors:  Xue-Yuan Dong; Carmen Rodriguez; Peng Guo; Xiaodong Sun; Jeffrey T Talbot; Wei Zhou; John Petros; Qunna Li; Robert L Vessella; Adam S Kibel; Victoria L Stevens; Eugenia E Calle; Jin-Tang Dong
Journal:  Hum Mol Genet       Date:  2008-01-17       Impact factor: 6.150

8.  Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.

Authors:  Angela Dispenzieri; Robert A Kyle; Jerry A Katzmann; Terry M Therneau; Dirk Larson; Joanne Benson; Raynell J Clark; L Joseph Melton; Morie A Gertz; Shaji K Kumar; Rafael Fonseca; Diane F Jelinek; S Vincent Rajkumar
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

9.  Implication of snoRNA U50 in human breast cancer.

Authors:  Xue-Yuan Dong; Peng Guo; Jeff Boyd; Xiaodong Sun; Qunna Li; Wei Zhou; Jin-Tang Dong
Journal:  J Genet Genomics       Date:  2009-08       Impact factor: 4.275

10.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

Authors:  Robert A Kyle; Ellen D Remstein; Terry M Therneau; Angela Dispenzieri; Paul J Kurtin; Janice M Hodnefield; Dirk R Larson; Matthew F Plevak; Diane F Jelinek; Rafael Fonseca; Lee Joseph Melton; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

View more
  19 in total

1.  Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.

Authors:  M Gkotzamanidou; E Terpos; C Bamia; S A Kyrtopoulos; P P Sfikakis; M A Dimopoulos; V L Souliotis
Journal:  Leukemia       Date:  2013-10-03       Impact factor: 11.528

Review 2.  C/D-box snoRNAs form methylating and non-methylating ribonucleoprotein complexes: Old dogs show new tricks.

Authors:  Marina Falaleeva; Justin R Welden; Marilyn J Duncan; Stefan Stamm
Journal:  Bioessays       Date:  2017-05-15       Impact factor: 4.345

3.  Dual function of C/D box small nucleolar RNAs in rRNA modification and alternative pre-mRNA splicing.

Authors:  Marina Falaleeva; Amadis Pages; Zaneta Matuszek; Sana Hidmi; Lily Agranat-Tamir; Konstantin Korotkov; Yuval Nevo; Eduardo Eyras; Ruth Sperling; Stefan Stamm
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-08       Impact factor: 11.205

4.  Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.

Authors:  Adrian A Carballo-Zarate; L Jeffrey Medeiros; Lianghua Fang; Jatin J Shah; Donna M Weber; Sheeba K Thomas; Elisabet E Manasanch; Suyang Hao; Qi Shen; Robert Z Orlowski; Pei Lin; Xinyan Lu
Journal:  Mod Pathol       Date:  2017-03-10       Impact factor: 7.842

5.  An Expanded Landscape of Unusually Short RNAs in 11 Samples from Six Eukaryotic Organisms.

Authors:  Marine Lambert; Sara Guellal; Jeffrey Ho; Abderrahim Benmoussa; Benoit Laffont; Richard Bélanger; Patrick Provost
Journal:  Noncoding RNA       Date:  2022-05-19

Review 6.  Biology and clinical relevance of noncoding sno/scaRNAs.

Authors:  Thuy Cao; Sheeja Rajasingh; Saheli Samanta; Buddhadeb Dawn; Douglas C Bittel; Johnson Rajasingh
Journal:  Trends Cardiovasc Med       Date:  2017-08-12       Impact factor: 6.677

7.  Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.

Authors:  Lucía López-Corral; Luis Antonio Corchete; María Eugenia Sarasquete; María Victoria Mateos; Ramón García-Sanz; Encarna Fermiñán; Juan-José Lahuerta; Joan Bladé; Albert Oriol; Ana Isabel Teruel; María Luz Martino; José Hernández; Jesús María Hernández-Rivas; Francisco Javier Burguillo; Jesús F San Miguel; Norma C Gutiérrez
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

Review 8.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

9.  Next-generation sequencing reveals differentially expressed small noncoding RNAs in uterine leiomyoma.

Authors:  Tsai-Der Chuang; Yeming Xie; Wei Yan; Omid Khorram
Journal:  Fertil Steril       Date:  2018-05       Impact factor: 7.329

10.  The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma.

Authors:  D Ronchetti; K Todoerti; G Tuana; L Agnelli; L Mosca; M Lionetti; S Fabris; P Colapietro; M Miozzo; M Ferrarini; P Tassone; A Neri
Journal:  Blood Cancer J       Date:  2012-11-23       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.